Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Roivant Sciences (NASDAQ:ROIV) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 0 | 0 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 4 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $18.33, a high estimate of $23.00, and a low estimate of $15.00. This upward trend is evident, with the current average reflecting a 12.8% increase from the previous average price target of $16.25.
Analyzing Analyst Ratings: A Detailed Breakdown
The standing of Roivant Sciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $18.00 | $18.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $18.00 | - |
| Corinne Jenkins | Goldman Sachs | Raises | Buy | $18.00 | $16.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $18.00 | $17.00 |
| Neena Bitritto-Garg | Deutsche Bank | Raises | Buy | $15.00 | $14.00 |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $23.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Roivant Sciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Roivant Sciences compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Roivant Sciences's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Roivant Sciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Roivant Sciences analyst ratings.
Delving into Roivant Sciences's Background
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Roivant Sciences's Economic Impact: An Analysis
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Roivant Sciences's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 5.68%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -522.35%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Roivant Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -2.51%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Roivant Sciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.08%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.08.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.